NCT05391581

The Role of GIP and GLP-2 in Postprandial Splanchnic Blood Flow Distribution and Metabolism

The Role of the Intestinal Hormones Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide 2 (GLP-2) in Postprandial Splanchnic Blood Flow Distribution and Metabolism in Humans

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of Copenhagen · Academic / Other
• Sex: Male
• Age: 20 Years – 70 Years
• Healthy volunteers: Accepted

Summary

This project will describe the mechanisms of action and the relative contributions of GIP and GLP-2 to changes in gastrointestinal blood flow induced by oral glucose, exogenous GIP and GLP-2 infusions, and endogenous GIP and GLP-2 with the use of two novel receptor antagonists GIP(3-30)NH2 and GLP-2(3-33) in healthy individuals.

Detailed description

Each participant will attend eight independent randomised experimental days in the MRI-scanner with intravenous infusion (hormone/placebo), subcutaneous injection (hormon/placebo) and oral ingestion (glucose/water). On experimental day A-C, an intravenous infusion of saline, GIP(3-30)NH2, or GLP-2(3-33), respectively, starts at time point -20 minutes. On experimental day D-F, the same infusions are combined with an oral glucose tolerance test (75 gram of glucose dissolved in 250 ml water ingested orally) at time point 0 minutes. On experimental days G-H, a subcutaneous injection of either GIP or GLP-2 at time point 0 minutes is performed (positive control) during saline infusion and oral water ingestion. MRI measurements are repeatedly performed and blood samples are drawn to be analysed for endocrine responses from the intestines, pancreas, and bones.

Conditions

• Blood Flow

Interventions

Type	Name	Description
OTHER	GIPR antagonist / study tool	Selective antagonist of the GIPR, GIP(3-30)NH2
OTHER	GLP-2R antagonist / study tool	Selective antagonist of the GLP-2R, GLP-2(3-33)
OTHER	Placebo	Saline

Timeline

• Start date: 2022-01-13
• Primary completion: 2023-02-07
• Completion: 2023-02-07
• First posted: 2022-05-26
• Last updated: 2023-12-26

Locations

1 site across 1 country: Denmark